Products Parasympatholytics are commercially available, for example, in the form of tablets, capsules, solutions, as inhalation preparations, injection solutions, and eye drops. This article refers to antagonists at muscarinic acetylcholine receptors. Antagonists at nicotinic acetylcholine receptors, such as ganglion blockers, are discussed separately. Structure and properties Many parasympatholytics are structurally derived from atropine, a natural … Parasympatholytics
Products Fesoterodine is commercially available in the form of sustained-release tablets (Toviaz). It has been approved in the EU since 2007 and in many countries since 2008. Structure and properties Fesoterodine (C26H37NO3, Mr = 411.58 g/mol) is present in drugs as fesoterodine fumarate. It is an ester prodrug and is rapidly and completely hydrolyzed to … Fesoterodine
Products Tolterodine is commercially available in the form of sustained-release capsules (Detrusitol SR). It has been approved in many countries since 2000. Its successor product, fesoterodine (Toviaz), was launched in 2008 and desfesoterodine (Tovedeso) in 2019. A non-retarded preparation is also commercially available in the United States (Detrol). Structure and properties Tolterodine (C22H31NO, Mr = … Tolterodine
Symptoms Irritable bladder manifests itself in the following symptoms. By definition, there are no pathologic changes of the genitourinary tract: Strong urge to urinate, which is difficult to suppress. Increased urinary frequency during the day Nighttime urination Urinary incontinence: an involuntary loss of urine may occur The constant urge reduces the quality of life and … Hyperactive Bladder
Symptoms Urinary incontinence manifests as involuntary leakage of urine. The common problem poses a psychosocial challenge for those affected, which can lead to changes in personal activities and a loss of quality of life. Risk factors include female gender, age, obesity, and numerous medical conditions. Causes Urinary incontinence can occur as a result of pathologic, … Urinary Incontinence: Causes and Treatment
Products Desfesoterodine was approved in many countries in 2019 in sustained-release tablet form (generic, tovedeso). Structure and properties Desfesoterodine (C22H31NO2, Mr = 341.5 g/mol) is the active metabolite of the prodrug fesoterodine as well as tolterodine (detrusitol). It is also referred to as 5-hydroxymethyltolterodine. In the drug, it is present as desfesoterodine succinate. Effects Desfesoterodine … Desfesoterodine
